{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "amendmentDetails": {
    "studyAmendmentImpacts": [
      {
        "id": "impact_1",
        "amendmentId": "INT-6",
        "affectedSection": "Synopsis (Statistical Methods); 11.3.5 Interim Analysis",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Reduction in the number of primary composite events required for the interim analysis from 540 to 405."
      },
      {
        "id": "impact_2",
        "amendmentId": "INT-6",
        "affectedSection": "Synopsis (Secondary Efficacy Outcomes); 9.4.2 Efficacy Outcomes",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "Addition of 3-point MACE and hospitalized congestive heart failure as new secondary endpoints."
      },
      {
        "id": "impact_3",
        "amendmentId": "INT-6",
        "affectedSection": "12 Adverse Event Reporting",
        "impactLevel": "Minor",
        "instanceType": "StudyAmendmentImpact",
        "description": "Designation of pancreatitis as an adverse event of special interest requiring 24-hour reporting."
      },
      {
        "id": "impact_4",
        "amendmentId": "INT-5",
        "affectedSection": "4.2 Exclusion Criteria",
        "impactLevel": "Major",
        "instanceType": "StudyAmendmentImpact",
        "description": "New exclusion criteria for subjects at high risk of lower extremity amputation."
      }
    ],
    "studyAmendmentReasons": [
      {
        "id": "reason_1",
        "amendmentId": "INT-6",
        "reasonText": "Decrease the number of primary composite events required for the interim analysis to allow for earlier detection of beneficial effects.",
        "category": "Scientific",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_2",
        "amendmentId": "INT-5",
        "reasonText": "Include new safety information and guidance regarding subject management surrounding the event of lower extremity amputations.",
        "category": "Safety",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      },
      {
        "id": "reason_3",
        "amendmentId": "INT-4",
        "reasonText": "Slower than expected recruitment early in the study required sample size expansion to maintain study timeline.",
        "category": "Operational",
        "isPrimary": true,
        "instanceType": "StudyAmendmentReason"
      }
    ],
    "studyChanges": [
      {
        "id": "change_1",
        "amendmentId": "INT-6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "11.3.5",
        "beforeText": "540",
        "afterText": "405",
        "summary": "Reduced the number of primary composite events required for the interim analysis."
      },
      {
        "id": "change_2",
        "amendmentId": "INT-6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "10.2.1",
        "beforeText": "required",
        "afterText": "initiated",
        "summary": "Clarified that study medication is discontinued when chronic dialysis or renal transplant is initiated."
      },
      {
        "id": "change_3",
        "amendmentId": "INT-6",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "Synopsis",
        "beforeText": "The Lan-DeMets alpha spending function approach will be used",
        "afterText": "The alpha spending function will be used",
        "summary": "Simplified the description of the statistical method used for alpha spending."
      },
      {
        "id": "change_4",
        "amendmentId": "INT-2",
        "changeType": "Modification",
        "instanceType": "StudyChange",
        "sectionNumber": "4.2",
        "beforeText": "≤10.5%",
        "afterText": "≤12.0%",
        "summary": "Increased the upper limit of HbA1c level for study entry."
      },
      {
        "id": "change_5",
        "amendmentId": "INT-5",
        "changeType": "Addition",
        "instanceType": "StudyChange",
        "sectionNumber": "4.2",
        "afterText": "Exclusion criteria 16: history of atraumatic amputation within past 12 months, or active skin ulcer, osteomyelitis, gangrene, or critical ischemia within 6 months.",
        "summary": "Added exclusion criteria for subjects at risk of amputation."
      }
    ],
    "summary": {
      "impactCount": 4,
      "reasonCount": 3,
      "changeCount": 5
    }
  }
}